Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 9;45(1):e20210309.
doi: 10.1590/1678-4685-GMB-2021-0309. eCollection 2022.

Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm

Affiliations

Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm

Yuri Yépez et al. Genet Mol Biol. .

Abstract

Our goal was to describe in more detail the evolutionary history of Gamma and two derived lineages (P.1.1 and P.1.2), which are part of the arms race that SARS-CoV-2 wages with its host. A total of 4,977 sequences of the Gamma strain of SARS-CoV-2 from Brazil were analyzed. We detected 194 sites under positive selection in 12 genes/ORFs: Spike, N, M, E, ORF1a, ORF1b, ORF3, ORF6, ORF7a, ORF7b, ORF8, and ORF10. Some diagnostic sites for Gamma lacked a signature of positive selection in our study, but these were not fixed, apparently escaping the action of purifying selection. Our network analyses revealed branches leading to expanding haplotypes with sites under selection only detected when P.1.1 and P.1.2 were considered. The P.1.2 exclusive haplotype H_5 originated from a non-synonymous mutational step (H3509Y) in H_1 of ORF1a. The selected allele, 3509Y, represents an adaptive novelty involving ORF1a of P.1. Finally, we discuss how phenomena such as epistasis and antagonistic pleiotropy could limit the emergence of new alleles (and combinations thereof) in SARS-COV-2 lineages, maintaining infectivity in humans, while providing rapid response capabilities to face the arms race triggered by host immuneresponses.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare that there are no conflicts of interest that could be understood as prejudicial to this research.

Similar articles

Cited by

References

    1. Abdool Karim S, de Oliveira T. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. N Engl J Med. 2021;384:1866–1868. - PMC - PubMed
    1. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi A, Memish ZA. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis. 2019;29:48–50. - PMC - PubMed
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–452. - PMC - PubMed
    1. Awadasseid A, Wu Y, Tanaka Y, Zhang W. SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. Int J Biol Sci. 2021;17:97–106. - PMC - PubMed
    1. Bager P, Wohlfahrt J, Fonager J, Albertsen M, YssingMichaelsen T, HoltenMøller C, Ethelberg S, Legarth R, Fischer Button MS, Gubbels SM, et al. Increased risk of hospitalization associated with infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark. SSRN Electron J. 2021 doi: 10.2139/ssrn.3792894. - DOI - PMC - PubMed